HUTCHMED (China) Limited (HCM), a commercial-stage biopharmaceutical company, which delivered impressive financial results in 2023, has set its sights on further growth in China.
The company's marketed drugs in China include ELUNATE (fruquintinib) for the treatment of metastatic colorectal cancer, SULANDA (Surufatinib) for the treatment of pancreatic and non-pancreatic neuroendocrine tumors, and ORPATHYS (Savolitinib) indicated for lung cancer with MET gene alterations.
For comments and feedback contact: editorial@rttnews.com
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.